Peer Review History
| Original SubmissionJuly 10, 2020 |
|---|
|
PONE-D-20-21404 The GTS-QOL (Gilles de la Tourette Syndrome–Quality of Life Scale): cross cultural evaluation of the French version PLOS ONE Dear Dr. Jalenques, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Nov 14 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Sandra Carvalho Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide. 3. One of the noted authors is a group; The Syndrome de Gilles de La Tourette Study Group. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: I Don't Know ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Review of: The GTS-QOL (Gilles de la Tourette Syndrome–Quality of Life Scale): cross-cultural evaluation of the French version The document contains excellent work to illustrate the conditions for the GTS-QOL-French version. All protocols and analytical steps are relevant and necessary for future scientific and clinical consideration. My humble observations are just a few: 1. Why called it a “Cross-cultural” adaptation? I thought you maybe need a more unnecessary description of procedures, like other authors suggested before (i.e., Borsa, Damásio & Bandeira, 2012). Just called validation or cross-validation is enough. 2. Check all document for colloquial expressions (i.e., “very good acceptability”). 3. I thought a desirable description of the validation process should sound like the next paragraphs when your process fit it in (this a frame inspired by Cavanna et al., 2013): Initially, the forward-backward procedure was applied to translate the GTS-QOL from English into ________ (Stage 1: scale translation). Two professional translators translated the questionnaire into _______ (“forward translation”). The resultant version was backwards translated into English (“backward translation”) by ____(number of) blind professional translators. The authors compared the two translated versions with the original English version, to yield the linguistic validation of the provisional questionnaire in ___________. In order to check the Italian population’s understanding and interpretation of the translated items, the questionnaire was pre-tested on ____(number of) patients with GTS (clinical sample). The results were discussed between experts and patients. This process led to a new _________ version of the GTS-QOL. Secondly, this scale was adapted for adolescents and adults through the following steps (Stage 2: scale adaptation): 1. ____(number of) clinicians with expertise in the management of adolescents and adults with GTS independently suggested how to simplify and rephrase items that they considered to be confusing for _____, and how to change the context of items referring to adult life (e.g. job) to fit with an adolescent’s routine (i.e., high school life). 2. The experts’ opinions for each of the 27 items were compared and discussed with patients with GTS, and the questionnaire was modified accordingly. The GTS patients no express any remarkable difficult to understand any item. 3. The questionnaire was administered to ______ (number of) adolescents and ______ (number of) adults randomly selected from a nonclinical sample (school population). The recruited subjects were asked to comment on the comprehensibility of the items and to put them into their own words. 4. The same expert clinicians made wording adjustments. 5. The adjusted questionnaire was administered to ______ (number of) adolescents and ______ (number of) adults to identify any further confusing items or words. Items rated as confusing by ____% of the total sample were reworded or replaced. Thirdly, the psychometric properties of the GTS-QOL have examined in an independent sample of ______ (number of) patients with GTS, described in Table _____. 4. Move “Table 1” to upper pages in the Participants sample section. 5. Participants should be described formally, sounding like this: The final sample was recruited from three French specialist centres (GTS Reference Centre (Paris), GTS Competence Centre (Clermont- Ferrand), the “Association Française Syndrome Gilles de la Tourette”). Participants were aged 16–64 years and had no ______ (Type of) disabilities or other neurological conditions, and met DSM-IV-TR criteria for the diagnosis of GTS. Neuropsychiatrists evaluated all participants with substantial expertise in the management of GTS, who performed the neurological examination, clinical interview and cognitive evaluation. 6. There are no changes between the original GTS-QOL questionnaire and the French version (Could you name it something like GTS-QOL-French”)? In lines 160 to 176, you talked about two versions, the original and the French. This information is required before, not with the analysis conducted and reported in results, but in a straightforward way to the reader when described the applied instrument. 7. Please present first all instruments and them the Data collection information restricted to how the instruments were administrated. 8. Please, check your Results’ ordination and my suggestion: Original document Suggestion (use it for results and discussion) (i) Factor analysis. Data completeness. (ii) Data completeness. (ii) Descriptive statistics and score distributions + Association between sociodemographic and clinical characteristics and GTS-QOL subscale scores (Lines 99 till 135). (iii) Descriptive statistics and score distributions. (iii) Internal consistency: Cronbach’s α coefficient (iv) Internal consistency: Cronbach’s α coefficient (iv) Inter-subscale correlations: Spearman’s coefficients (v) Item-total correlations (v) Factor analysis. (vi) Inter-subscale correlations: Spearman’s coefficients (vi) Item-total correlations (vii) Convergent validity:TherelationshipsbetweenGTS-QOLand(1)WHOQOL-BREF,(2) MOVES subscales and (3) GTS-QOL VAS were studied, by calculating Spearman ρ correlation coefficients. (vii) Reliability (viii) Reliability: Stability over time was assessed by the test-retest method. Reliability of the subscales was estimated by intraclass correlation coefficient (ICC), (viii) Convergent validity 9. Line 148, please pause with a period: 148. of tic severity in GTS than cases recruited solely in tertiary centres. As suggested by comparison … 10. Line 159, the subtitle is not necessary (or you need to include all other subtitles sections): 159. Cross-cultural evaluation of the French version of the GTS-QOL 11. Line 177, if you assume my suggestion for results’ order, might be the first Discussion’s section line. 12. Line 206 (p. 28), “Of note…” is colloquial. 13. Line 249 (p. 30), please check the English language. 14. About Discussion: Some lines are evident and repeat information reported in Results. Otherwise, some require a better explanation, as an example: “Reference Centre, a Competence Centre and a patient association and thus might be more representative of the different levels of tic severity in GTS than cases recruited solely in tertiary centres (Lines 146-148)” Why those centres have more representative population in France? 15. Please consider APA guidelines for citation in expressions like: “echo phenomena, were low in our participants compared to the scores reported in the study of Gaffney [18] and in that which validated the original version of the GTS-QOL [11]. (Lines 188-189)”. 16. Lines 208-220 contain an explanation for no significant correlation between WHOQOL-BREF subscales and some subscales of the GTS-QOL. The explanation indicates “There are no common characteristics” between not correlated subscales. I know that it is not an objective for the study. However, following Balsamo, Innamorati, & Lamis (2019), you might comment about the difficulty for integrating psychometrics and clinical views when inter-scales analysis allows us to go further and against apparent conclusions. 17. Why there are not any health or well-being policy recommendations about GTS population and benefits for using GTS-QOL-French (i.e., French-speaking caregivers of GTS population more directly informed about the life-quality of their adolescents and adults? References Balsamo, M., Innamorati, M., & Lamis, D. A. (2019). Editorial: Clinical Psychometrics: Old Issues and New Perspectives. Frontiers in psychology, 10, 947. https://doi.org/10.3389/fpsyg.2019.00947 Cavanna, A. E., Luoni, C., Selvini, C., Blangiardo, R., Eddy, C. M., Silvestri, P. R., Calì, P. V., Seri, S., Balottin, U., Cardona, F., Rizzo, R., & Termine, C. (2013). The Gilles de la Tourette Syndrome-Quality of Life Scale for children and adolescents (C&A-GTS-QOL): development and validation of the Italian version. Behavioural neurology, 27(1), 95–103. https://doi.org/10.3233/BEN-120274 Reviewer #2: Summary: In this manuscript [“The GTS-QOL (Gilles de la Tourette Syndrome–Quality of Life Scale): cross cultural evaluation of the French version”], Jalenques et al. present the methodology and results underlying the development of a French version of the GTS-QOL. The analyzed sample (109 participants aged 16-years old or above) and applied analyzes seem appropriate, and the results are overall quite satisfying; thus, I see no reason for this manuscript not to be accepted in PLOS ONE, provided that, at least, the following comments/doubts are addressed. (I hope that you find them helpful, and please note that some of my comments/doubts might apply to several parts of the manuscript; not only to the quoted portions that I pasted below.) Main comments: The manuscript is very well written and easy to follow; thus, I would like to start by congratulating the authors. In its current state, however, the Discussion of the manuscript seems a bit poor. Several portions of text are too descriptive, lacking a more comprehensive interpretation of the results and, perhaps more importantly, of the pros and cons of the French version of the GTS-QOL presented here. Several flaws of the developed version are indicated in the “Results” section, namely the abnormal loading of some items and the considerable floor effects for some of its subscales. The latter, for instance, seems very problematic if one desires to apply this scale to patients with lower symptom severity, meaning that, in the future, researchers that wish to use this scale will necessarily have to use carefully designed recruitment strategies... Otherwise, this version might not be suitable. Although I am not an expert in the GTS-QOL, I am aware of, at least, an Italian version of this questionnaire. Even though such translated version was applied to children and adolescents (which complicates the interpretation of its properties in comparison to the version here presented), I think that it would greatly improve the paper to discuss the results from the French version in comparison not only to the original version but also in comparison to other translated versions of the scale. If possible, the focus should be on versions validated in adults, but, if that is not possible, I think that even the analysis of the versions validated in children and adolescents might provide valuable information to a reader that desires to better understand the pros and cons of this version. Main doubt: Should not the translated version of the scale be made available with the article? Other (minor) comments/doubts: 1. Mentioning “very good acceptability” in the Abstract, providing no quantitative measure of such acceptability, seems suboptimal. 2. Using “ICC” without introducing the acronym in the Abstract seems suboptimal too, but I am guessing that might relate to the maximum number of characters allowed in the Abstract… 3. The choice of the MOVES and WHOQOL-BREF scales should be more comprehensively explained so that it is easier for the readers to follow the authors rationale from the beginning. 4. It would be nice to incorporate some quantitative information into this following sentence: “It had good acceptability, validity, internal consistency and test-retest reliability”. 5. The rationale underlying the selection of the exact subsample that was used to assess the scale’s reliability should be much better explained. 6. Are the “quality criteria” from references 13 and 14 independent from the specific properties of the questionnaire? It would make sense that they were dependent on the total number of questions, number of questions per subscale, etc. Can you please clarify? 7. In the “The GTS-QOL questionnaire” subsection of the Methods, the number of items per subscale should be mentioned. 8. “Good understanding and content validity was shown for all items.”: Can you please explain how was this “shown”? 9. “The generic WHOQOL-BREF questionnaire comprised 26 items which are grouped into four subscales: ‘Physical health’, ‘Psychological health’, ‘Social relationships’ and ‘Environment’. For each subscale, scores are rated between 0 and 100, with higher values indicating better HRQoL”: Should maybe emphasize that this is contrary to GTS-QOL and indicate how many items per subscale in the sentence above. 10. Some references seem to be missing in: “Factor analysis: Factor analysis with the principal axis extraction method and oblique promax rotation were performed to study the multidimensionality and distribution of the items in subscales.” 11. The authors mention that “Eigenvalues higher than 1 (Kaiser criterion) and Cattell’s scree plot [24] were used to verify factor solution accuracy”, but then fail to address exactly how they did so. 12. Given that tests were two-tailed, the use of “attempted” rather than, e.g., “expected”, in page 14, seems suboptimal. 13. It was not clear for me what were the independent groups in “Finally, comparisons of GTS-QOL subscale scores between independent groups (…)”. 14. Not sure that the use of “more” in the beginning of page 15 is correct. Should not it be “lower”? 15. Table 1 seems to have some errors. Some of the categories should add to 100% and that is not the case. In some categories that might have been simply due to rounding errors (e.g., “Education”) while in others (e.g., “Comorbidities”) that does not seem to be the case. 16. In Table 2, I think that it would be helpful to indicate the maximum possible values too, to facilitate the interpretation of the presented values. 17. The rationale for keeping item 4 in factor 5 was not clear; it seemed a somewhat odd choice, especially given the relation between phonic tics and some of the items in the “Echo-coprophenomena” scale. 18. The designation of “Cognitive” seems somewhat misleading, given the nature of the items in that scale, but I guess that might be due to the original English version… 19. In Table 5, the problematic items (9, 10, and possibly 15 too) from the “Obsessive-compulsive” scale should be highlighted somehow, so that the readers can identify them more easily. 20. In page 20, I think it would be better to specify some of the values instead of only mentioning “small” or “moderate” correlations. 21. Are all p-values in Table 7 correct? It would seem more logical if they were 0.01 and 0.001 instead, given that * corresponds to 0.05. 22. Can you please explain if the EuroQol-5D has important flaws that one should be aware? That would help understanding why you suggested a different approach. 23. I do not quite agree with the following sentence: “These observations are evidence that psychological 234 considerations are those that have the greatest influence on the HRQoL of GTS subjects”. Psychological symptoms might themselves be a direct consequence of the severity of Tourette syndrome and/or comorbidities symptoms… Typos: 1. There is an extra “)” following “[15]” in the “Translation and cultural adaptation of the GTS-QOL” subsection. 2. There is a blank space missing before “[28]”. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Juan J Giraldo-Huertas Department of Development and Education Psychology Universidad de la Sabana Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Cross-cultural adaptation and psychometric evaluation of the French version of the Gilles de la Tourette Syndrome Quality of Life Scale (GTS-QOL) PONE-D-20-21404R1 Dear Dr. Jalenques, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Sandra Carvalho Academic Editor PLOS ONE |
| Formally Accepted |
|
PONE-D-20-21404R1 Cross-cultural adaptation and psychometric evaluation of the French version of the Gilles de la Tourette Syndrome Quality of Life Scale (GTS-QOL) Dear Dr. Jalenques: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Sandra Carvalho Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .